Advances in the Treatment of Relapsed/Refractory Immune Thrombocytopenia With Keith McCrae, MD, and Phyllis McKiernan, APN, MSN, OCN®

Immune thrombocytopenia is an acquired immune-mediated disorder defined as a peripheral blood platelet count <100 x109/L with no known cause (Rodeghiero et al, 2009). The incidence is estimated to be 1.6 to 3.9 per 100,000 patient-years in adults and 0.46 to 12.5 per 100,000 patient-years in children (Terrell et al, 2010). Research has shown that the burden of ITP is significant. A survey of more than 1,300 patients across 13 countries showed 36% reported a high impact on emotional well-being...
Continue reading

New Perspectives on Diagnosis and Treatment of EGFR Exon 20 Insertion–Mutant NSCLC With Helena Yu, MD, and Maria Arcila, MD

An estimated 235,760 new cases of lung cancer are reported in the United States annually, and 131,880 people die of the disease. Approximately 84% of cases are classified as non-small cell lung cancer (NSCLC) (ACS, 2021). The most frequent genomic aberration among patients with NSCLC is the epidermal growth factor receptor (EGFR) mutation, approximately 2%-10% of which are exon 20 insertion mutations (Kumari et al, 2019; Dersarkissian et al, 2019). Exon 20 insertion mutations are a heterogenous ...
Continue reading

New Opportunities in Advanced KRAS Mutation–Positive NSCLC With D. Ross Camidge, MD, PhD, and Beth Sandy, MSN, CRNP, OCN®

An estimated 228,820 new cases of lung cancer are reported in the United States annually, and 135,720 people die of the disease (ACS, 2020). Approximately 84% of cases are classified as non-small cell. Most patients are diagnosed at a locally advanced or metastatic stage, making systemic therapy the cornerstone of management (ACS, 2020). Although 70% of patients receiving first-line classical doublet chemotherapy demonstrate clinical benefit, most develop progressive disease within 5 months of t...
Continue reading

Burnout: Prevention and Coping Tactics for Oncologists With Daniel McFarland, DO

Physician burnout and work-related stress are serious and prevalent issues in oncology, with nearly 45% of oncologists experiencing signs of burnout. Recently, this problem has been further exacerbated by the challenges brought about by the COVID-19 pandemic. In this episode of Oncology Data Advisor, Daniel McFarland, DO, a head and neck medical oncologist and consult-liaison psychiatrist at Northwell Health Lenox Hill Hospital, joins i3 Health for a discussion that covers the varying factors th...
Continue reading

Update on Immunotherapeutic Strategies for Advanced Merkel Cell Carcinoma With Shailender Bhatia, MD and Ciara Kelly, MBBCh, BAO

Merkel cell carcinoma is a rare and aggressive neuroendocrine tumor of unknown origin that typically presents in older white and immunocompromised adults. An estimated 2,488 cases are diagnosed in the United States annually (Paulson et al, 2018). The incidence of MCC has risen rapidly during the past few decades, which has been attributed in part to people living longer with increased sun exposure and weakened immune systems, a feature that suggests an infectious origin and warrants further rese...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.